SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) is presenting new data this week showing that its drug candidate HE3286, a novel orally bio-available small molecule compound that has previously demonstrated significant benefit in rodent models of rheumatoid arthritis (RA), also provided benefit in an animal model of multiple sclerosis (MS). The Company is presenting data this week at the 2nd International Congress on Immune-Mediated Diseases being held in Moscow, Russia. In addition the Company is presenting preclinical data demonstrating that HE3286, along with other novel compounds under investigation, HE3413 and HE3177, appear to act by limiting the activation of the pro-inflammatory transcription factor NF-kappaB.
